<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557099</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-SAA-II</org_study_id>
    <nct_id>NCT03557099</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient</brief_title>
  <official_title>A Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicentre, Open-label, single-arm, Phase II Study to Evaluate the Safety and
      Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia.

      55 adult patients with SAA will be enrolled in the study. Treatment with Hetrombopag will be
      started at 7.5 mg/day and uptitrated according to the platelet count. The primary objective
      of the study is to assess the safety and efficacy of Hetrombopag in patients with SAA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Hematological Response</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>Hematological Response is defined by changes in the platelet count or platelet transfusion requirements, hemoglobin levels or number of red blood cell transfusions, neutrophil counts or G-CSF usage requirements.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <description>once daily</description>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previous diagnosis of refractory severe aplastic anemia, not meeting partial response
             criteria after at least one treatment course of immunosuppressive therapy, not
             suitable or unwilling to do hematopoietic stem cell transplantation.

          2. Platelet count ≤ 30×109/L.

          3. Signed informed consent.

        Exclusion Criteria:

          1. Bleeding and/or Infection not adequately responding to appropriate therapy.

          2. Patients with a PNH clone size in neutrophils of ≥50%.

          3. Treatment with immunosuppressive therapy within 6 months prior to study entry.

          4. Any laboratory or clinical evidence for HIV infection. Any clinical history for
             hepatitis C infection; chronic hepatitis B infection; or any evidence for active
             hepatitis at the time of subjects screening.

          5. ALT&gt; 2.5 x upper limit of normal (ULN), AST&gt; 2.5 x upper limit of normal (ULN) DBLI&gt;
             1.5 x upper limit of normal (ULN), Scr&gt; upper limit of normal (ULN).

          6. Subjects diagnosed with cirrhosis or portal hypertension.

          7. Subjects diagnosed with tumor.

          8. Patients with any prior history of congestive heart failure, arrhythmia, and
             peripheral arteriovenous thrombosis within 1 year. With a history of myocardial
             infarction or cerebral infarction within 3 months.

          9. ECOG Performance Status of 3 or greater.

         10. Female subjects who are nursing or pregnant within 6 months.

         11. Subjects cannot take effective contraception.

         12. Subjects have participated in other clinical trial within the 3 months prior to study
             entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ya-Qi Shen, Ph.D.</last_name>
    <phone>+86-021-50118402</phone>
    <email>shenyq@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Li, Ph.D.</last_name>
    <phone>+86-021-50118402</phone>
    <email>karenli@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengkui Zhang, MD</last_name>
      <email>zhfk@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 3, 2018</study_first_submitted>
  <study_first_submitted_qc>June 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

